Rein in Sarcoma announced significant new research grants totaling $$65,000 at our recent Fall Fundraiser. For the second year, RIS awarded grants to researchers at Mayo Clinic and Children's Hospitals and Clinics of Minnesota. We also announced multi-year support for a SARC SPORE grant proposal. The evening included a new commitment to increase sarcoma research funding at the University of Minnesota to $150,000 in 2019.
Upon the review and recommendation of the Rein in Sarcoma Research Task Force, chaired by Dr. John L. Seymour, to the Board of Directors, RIS committed a $30,000 grant to Mayo Clinic for: “Pilot Study of Circulating Cell Free Tumor DNA as a Biomarker in Sarcoma” with Principal Investigator: Brittany L. Siontis, MD - Senior Associate Consultant, Department of Medical Oncology, and Co-investigator Steven Robinson, MBBS, Assistant Professor, Department of Medical Oncology.
In addition, Rein in Sarcoma awarded Children's Hospitals and Clinics of Minnesota a $15,000 research grant for: “Identifying Gene Fusions in Pleuropulmonary Blastoma”, with Principal Investigator: Kris Ann Schultz, MD Pediatric Oncologist; Co- investigator D. Ashley Hill, MD.
RIS also committed $20,000 over four years, beginning in 2019, to SARC (Sarcoma Alliance for Research through Collaboration) in Ann Arbor, Michigan in support of a SPORE proposal. This support is contingent on approval by the National Institute of Health (NIH).
NIH SPORE (Specialized Programs of Research Excellence) grants are multi-million dollar grants designed to bring cutting edge cancer research to the bedside within five years. If approved by the NIH in 2019, the research will be conducted by several major medical research institutions across the country. Read information about the current Sarcoma SPORE project at SARC.
The RIS Research Task Force is working on plans to hold our first Rein in Sarcoma Research Collaborative Symposium in spring 2019. This event will bring together RIS research grantees to present and discuss their sarcoma research projects. More to come...